Business Context and Reporting Period
This Form 8-K Current Report from Aptevo Therapeutics Inc. (APVO) covers the event date of December 29, 2025. The filing details the implementation of a reverse stock split approved by the Board of Directors on December 17, 2025, following stockholder authorization at a Special Meeting on July 24, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure adjustments rather than operational financial performance.
Material Changes
- Reverse Stock Split: The Company effected a 1-for-18 reverse stock split effective at 5:01 p.m. Eastern Time on December 29, 2025.
- Share Consolidation: Every 18 issued and outstanding shares were automatically combined into one share without a change in par value.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on December 30, 2025, under the new CUSIP number 03835L702.
- Equity Instrument Adjustments: Proportionate adjustments were made to the exercise prices and share counts of outstanding stock options, restricted stock units, and warrants.
- Fractional Shares: No fractional shares were issued; record holders entitled to fractions received cash payments in lieu thereof.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the reverse stock split, noting that actual results may differ due to various risks. Key risks and contingencies identified include:
- The Company's ability to continue as a going concern.
- Deterioration in business prospects or further assessment of clinical trial data.
- Adverse events, safety issues, or unanticipated problems in clinical development.
- Changes in regulatory, social, macroeconomic, and political conditions.
Management disclaims any obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the new CUSIP number (03835L702) for post-split trading.
- Confirm the adjusted exercise prices and share counts for any held options, RSUs, or warrants.
- Review the Company's most recent 10-K or 10-Q filings for current liquidity status and going concern assessments.
- Check the status of cash payments for fractional shares if applicable to your holdings.